These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

757 related items for PubMed ID: 18975346

  • 1. Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.
    Keystone E, Heijde Dv, Mason D, Landewé R, Vollenhoven RV, Combe B, Emery P, Strand V, Mease P, Desai C, Pavelka K.
    Arthritis Rheum; 2008 Nov; 58(11):3319-29. PubMed ID: 18975346
    [Abstract] [Full Text] [Related]

  • 2. Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial.
    Smolen J, Landewé RB, Mease P, Brzezicki J, Mason D, Luijtens K, van Vollenhoven RF, Kavanaugh A, Schiff M, Burmester GR, Strand V, Vencovsky J, van der Heijde D.
    Ann Rheum Dis; 2009 Jun; 68(6):797-804. PubMed ID: 19015207
    [Abstract] [Full Text] [Related]

  • 3. Efficacy and safety of certolizumab pegol plus methotrexate in Japanese rheumatoid arthritis patients with an inadequate response to methotrexate: the J-RAPID randomized, placebo-controlled trial.
    Yamamoto K, Takeuchi T, Yamanaka H, Ishiguro N, Tanaka Y, Eguchi K, Watanabe A, Origasa H, Shoji T, Sakamaki Y, van der Heijde D, Miyasaka N, Koike T.
    Mod Rheumatol; 2014 Sep; 24(5):715-24. PubMed ID: 24313916
    [Abstract] [Full Text] [Related]

  • 4. Rapid and sustained improvements in health-related quality of life, fatigue, and other patient-reported outcomes in rheumatoid arthritis patients treated with certolizumab pegol plus methotrexate over 1 year: results from the RAPID 1 randomized controlled trial.
    Strand V, Mease P, Burmester GR, Nikaï E, Coteur G, van Vollenhoven R, Combe B, Keystone EC, Kavanaugh A.
    Arthritis Res Ther; 2009 Sep; 11(6):R170. PubMed ID: 19909548
    [Abstract] [Full Text] [Related]

  • 5. Effect of certolizumab pegol with methotrexate on home and work place productivity and social activities in patients with active rheumatoid arthritis.
    Kavanaugh A, Smolen JS, Emery P, Purcaru O, Keystone E, Richard L, Strand V, van Vollenhoven RF.
    Arthritis Rheum; 2009 Nov 15; 61(11):1592-600. PubMed ID: 19877104
    [Abstract] [Full Text] [Related]

  • 6. Two dosing regimens of certolizumab pegol in patients with active rheumatoid arthritis.
    Furst DE, Shaikh SA, Greenwald M, Bennett B, Davies O, Luijtens K, Staelens F, Koetse W, Bertin P.
    Arthritis Care Res (Hoboken); 2015 Feb 15; 67(2):151-60. PubMed ID: 25302624
    [Abstract] [Full Text] [Related]

  • 7. American College of Rheumatology hybrid analysis of certolizumab pegol plus methotrexate in patients with active rheumatoid arthritis: data from a 52-week phase III trial.
    van Vollenhoven RF, Felson D, Strand V, Weinblatt ME, Luijtens K, Keystone EC.
    Arthritis Care Res (Hoboken); 2011 Jan 15; 63(1):128-34. PubMed ID: 20799264
    [Abstract] [Full Text] [Related]

  • 8. Certolizumab pegol plus MTX administered every 4 weeks is effective in patients with RA who are partial responders to MTX.
    Choy E, McKenna F, Vencovsky J, Valente R, Goel N, Vanlunen B, Davies O, Stahl HD, Alten R.
    Rheumatology (Oxford); 2012 Jul 15; 51(7):1226-34. PubMed ID: 22344576
    [Abstract] [Full Text] [Related]

  • 9. Efficacy and safety of certolizumab pegol without methotrexate co-administration in Japanese patients with active rheumatoid arthritis: the HIKARI randomized, placebo-controlled trial.
    Yamamoto K, Takeuchi T, Yamanaka H, Ishiguro N, Tanaka Y, Eguchi K, Watanabe A, Origasa H, Iwai K, Sakamaki Y, van der Heijde D, Miyasaka N, Koike T.
    Mod Rheumatol; 2014 Jul 15; 24(4):552-60. PubMed ID: 24981319
    [Abstract] [Full Text] [Related]

  • 10. Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study.
    Fleischmann R, Vencovsky J, van Vollenhoven RF, Borenstein D, Box J, Coteur G, Goel N, Brezinschek HP, Innes A, Strand V.
    Ann Rheum Dis; 2009 Jun 15; 68(6):805-11. PubMed ID: 19015206
    [Abstract] [Full Text] [Related]

  • 11. Certolizumab pegol: in rheumatoid arthritis.
    Duggan ST, Keam SJ.
    BioDrugs; 2009 Jun 15; 23(6):407-17. PubMed ID: 19894782
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Efficacy and safety of certolizumab pegol in rheumatoid arthritis: meeting rheumatologists' requirements in routine clinical practice.
    Punzi L, Lapadula G, Mathieu A.
    BioDrugs; 2014 Apr 15; 28 Suppl 1():S25-37. PubMed ID: 24687236
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Certolizumab pegol (CDP870) for rheumatoid arthritis in adults.
    Ruiz Garcia V, Jobanputra P, Burls A, Cabello JB, Vela Casasempere P, Bort-Marti S, Kynaston-Pearson FJ.
    Cochrane Database Syst Rev; 2014 Sep 18; (9):CD007649. PubMed ID: 25231904
    [Abstract] [Full Text] [Related]

  • 16. Long-term efficacy and safety of certolizumab pegol in Japanese rheumatoid arthritis patients who could not receive methotrexate: 52-week results from an open-label extension of the HIKARI study.
    Tanaka Y, Yamamoto K, Takeuchi T, Yamanaka H, Ishiguro N, Eguchi K, Watanabe A, Origasa H, Shoji T, Miyasaka N, Koike T.
    Mod Rheumatol; 2014 Sep 18; 24(5):725-33. PubMed ID: 24372225
    [Abstract] [Full Text] [Related]

  • 17. Long-term efficacy and safety of certolizumab pegol in Japanese rheumatoid arthritis patients with an inadequate response to methotrexate: 52-week results from an open-label extension of the J-RAPID study.
    Tanaka Y, Yamamoto K, Takeuchi T, Yamanaka H, Ishiguro N, Eguchi K, Watanabe A, Origasa H, Shoji T, Miyasaka N, Koike T.
    Mod Rheumatol; 2014 Sep 18; 24(5):734-43. PubMed ID: 24593170
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 38.